Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

ER - Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026

Company: Viromed Medical Date: 2025-06-30 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details 

Ad-hoc | 30 June 2025 15:36

#   

Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026

Viromed Medical AG / Key word(s): Forecast  

Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026  

  

30-Jun-2025 / 15:36 CET/CEST  

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026**

Pinneberg, June 30, 2025 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, expects dynamic sales growth in the coming financial years. In detail, revenue is expected to rise from EUR 1.37 million in 2024 to around EUR 8 million to EUR 10 million in 2025 and to increase almost tenfold to around EUR 80 million in 2026. The Management Board expects a slightly positive result for 2025 and an EBIT margin in the cleary double-digit range from 2026 onwards.

While revenue in 2025 will largely come from the operating business of the newly acquired Pharmedix GmbH, the new products ViroCAP® and, in particular, PulmoPlas® will contribute to dynamic growth in the 2026 financial year. The planned revenue is based on existing partnerships and distribution agreements.

Viromed’s low revenue in 2024 is due to the termination of its cooperation with terraplasma medical GmbH, which was announced in July 2024. According to preliminary figures, Viromed has already more than doubled its 2024 revenue in the first half of 2025. In addition, the new developed medical product ViroCAP® is expected to be delivered to customers from September 2025.

Person making the notification:  

Viromed Medical AG  

Management Board

  

  

End of Inside Information  

- - -

Information and Explanation of the Issuer to this announcement:  

  

**About Viromed Medical AG**

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

[www.viromed-medical-ag.de](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f97adabff932618f9d86cbcde35fa0ed&application_id=2162604&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3&application_name=news)

  

**Contact Viromed**

E-Mail: [kontakt@viromed-medical.de](mailto:kontakt@viromed-medical.de)  

**Press contact**

E-mail: viromed@kirchhoff.de

- - -

30-Jun-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Archive at www.eqs-news.com  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | Viromed Medical AG |
|     | Flensburger Straße 18 |
|     | 25421 Pinneberg |
|     | Germany |
| E-mail: | kontakt@viromed-medical.de |
| Internet: | https://www.viromed-medical-ag.de/ |
| ISIN: | DE000A3MQR65 |
| WKN: | A3MQR6 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange |
| EQS News ID: | 2162604 |

  

|     |     |
| --- | --- |
|     |     |
| End of Announcement | EQS News Service |

- - -

2162604  30-Jun-2025 CET/CEST

![](https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2162604&application_name=news&site_id=airport_aws~~~7cc68db1-74de-43c8-af69-2ae0a97efdc3)

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.